DGAP-News

CVR Medical Granted IRB Approval by Thomas Jefferson University Hospital

DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous
CVR Medical Granted IRB Approval by Thomas Jefferson University Hospital

12.01.2017 / 09:01
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2017) - CVR
Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical') is
pleased to announce that its 'Carotid Stenotic Scan' (CSS) device has
received IRB approval for clinical trials, to be conducted through the NIH
HF Network at Thomas Jefferson University Hospital under the supervision of
Dr. David J. Whellan , MD, MHS, FACC, FAHA.

CVR Chief Operations Officer Tony Robinson states, 'With IRB approval, we
look forward to continuing our progress through this final phase of
clinical trials. To be able to do so with Dr. Whellan at Thomas Jefferson
is something CVR is very proud of.'

For additional information on the organization, leadership, and current
news please visit the newly launched company website www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture
with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in
the medical industry focused on the commercialization of a proprietary
subsonic, infrasonic, and low frequency sound wave analysis technology and
has patents to a diagnostic device designed to detect and measure carotid
arterial stenosis. CVR Medical is managed by a proven technical team. CVR
Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:
(signed) 'Peter Bakema'
CEO, President & Director

For further information contact:

Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: [phone]

This press release contains forward-looking information that involves
various risks and uncertainties regarding future events related to the
Joint Venture. Such statements are subject to risks and uncertainties that
may cause actual results, performance or developments to differ materially
from those contained in the statements and are not guarantees of future
performance of the Company. No assurance can be given that any of the
events anticipated by the forward-looking statements will occur or, if they
do occur, what benefits the Company will obtain from them. These
forward-looking statements reflect management's current views and are based
on certain expectations, estimates and assumptions which may prove to be
incorrect. A number of risks and uncertainties could cause our actual
results to differ materially from those expressed or implied by the
forward-looking statements, including: (1) a downturn in general economic
conditions in North America and internationally, (2) the inherent
uncertainties and speculative nature associated with commercialization of
technology and the practice of medicine, (3) a change in health
regulations, (4) any number of events or causes which may delay or cease
commercialization and development of the Joint Venture, (5) the risk that
the Company or the Joint Venture does not execute its business plan, (6)
inability to retain key employees, (7) inability to finance operations and
growth, and (8) other factors beyond the Company's control. These
forward-looking statements are made as of the date of this news release
and, except as required by law, the Company assumes no obligation to update
these forward-looking statements, or to update the reasons why actual
results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE
CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF
THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.


Click on, or paste the following link into your web browser, to view
the associated documents

http://www.newsfilecorp.com/release/24472

News Source: Newsfile


---------------------------------------------------------------------------

12.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: CVR Medical Corp.


Canada
ISIN: CA1266321084



End of News DGAP News Service
---------------------------------------------------------------------------

535757 12.01.2017